logo celebrate FC

A Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in subjects with ST-elevation myocardial infarction in the pre-hospital setting


Zalunfiban is an investigational drug. It is a novel, promising and fast acting (5-15 minutes) GPIIbIIIa inhibitor with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. For patients with ST-elevation myocardial infarction (STEMI) early treatment with zalunfiban could be beneficial by improving initial patency of the infarct related vessel and by minimizing thrombotic occlusions, thus improving both coronary artery and myocardial microvascular blood flow, possibly resulting in a decrease in infarct size and a reduction in complications of STEMI.

The CeleBrate Trial is a phase 3 trial to assess the clinical outcome at 30 days follow-up after administration of a single subcutaneous injection of zalunfiban versus placebo in STEMI subjects in the pre-hospital setting.

Sites and inclusion

This multi-center study will be conducted at up to 45 clinical sites (hospitals/ambulance services) in Europe and North America. In the CeleBrate trial, a total of 2499 subjects will be enrolled within 2,5 years, with a 12-month follow‑up period.

The first patient was included in the Isala hospital/Ambulance IJsselland, Zwolle, the Netherlands on April 24, 2021.


CeleCor Therapeutics Inc. is the study sponsor.

Clinical investigators

Coordinating Principal Investigator:

Prof. A.W.J. Van ‘t Hof, MD PhD (Interventional cardiologist, Head interventional cardiology, MUMC+, Maastricht)

National Principal investigator for the Netherlands:

Prof. J.M. ten Berg, MD PhD (Interventional cardiologist St. Antonius hospital, Nieuwegein, and professor antithrombotic therapy in cardiac interventions, MUMC+, Maastricht)

National Principal Investigator for the Czech Republic:

Prof. P. Kala, MD PhD (Interventional cardiologist, Deputy Executive Director, head of cathlab at University Hospital Brno)

National Principal Investigator for Hungary:

Prof. B. Merkely, MD PhD (Interventional and sports cardiologist, professor and rector at Semmelweis University, director of Semmelweis University’s Heart and Vascular Centre, Budapest)


Rikken Sem AOF, Selvarajah Abi, Hermanides Renicus S et al. Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial. American Heart Journal, 2023 Apr; 258:119-128. doi: 10.1016/j.ahj.2022.12.015.

Clinical study information